PDMI Paradigm Medical Industries Inc (CE)

Paradigm Medical Industries, Inc. (OTCBB: PDMI) announced today that the Company intends to respond to a global need to fight a growing epidemic, glaucoma. At last month's World Glaucoma Day, groups around the globe came together with the National Eye Institute and part of the National Institutes of Health to recognize the blinding visual condition of glaucoma as a scientific research priority and a public health concern.

Glaucoma is one of the world's primary causes of vision loss, affecting nearly 70 million people worldwide, including an estimated 2.2 million Americans. An additional 2 million Americans remain undiagnosed. African-Americans over age 40 and all adults over age 60, especially Hispanics, are at a higher risk for the condition. Even with this striking prevalence, only 8 percent of Americans recently surveyed knew that glaucoma has no early warning signs.

Glaucoma usually begins silently during midlife with painless, gradual vision loss. Only an eye care professional can detect the subtle signs of glaucoma within the eye. Early detection offers an opportunity to stop or slow disease progression with eye drops or surgery. Regular, comprehensive dilated eye examinations are crucial because once vision is lost, it is gone forever.

Paradigm Medical intends to develop, locate, market and introduce new and innovative products for the glaucoma and ultrasound microscopy fields to provide the earliest possible detection of this disease.

"Glaucoma is a real and growing epidemic that continues to affect millions of lives globally," said Paradigm Medical President, Stephen Davis. "Our goal is to come out strong this year with innovative products that will offer early definitive diagnostic patient information to help fight and control glaucoma."

About Paradigm Medical Industries, Inc.

Headquartered in Salt Lake City, Utah, Paradigm Medical Industries, Inc. is a medical device company that develops, manufactures and distributes cutting edge, new innovative products in the diagnostic ultrasound and early glaucoma detection markets. Paradigm has the only patented technology utilizing photon laser for cataract removal. The Company is poised to capture a niche market within the glaucoma and ultrasound microscopy fields. Paradigm Medical Industries markets its products to ophthalmologists, optometrists, universities, and clinics throughout the United States, as well as internationally.

For more information, please visit: www.paradigm-medical.com

This press release contains statements that, if not verifiable historic fact, may be viewed as forward-looking statements that could predict future events and outcomes with respect to Paradigm and its business. The predictions embodied in these statements will involve risk and uncertainties and, accordingly, actual results may differ significantly from the results discussed or implied in such forward-looking statements.

Contact: Paradigm Medical Industries, Inc. Stephen Davis President 801-977-8970 www.paradigm-medical.com